N	B:C1706793
-	I:C1706793
Terminal	I:C1706793
Hypothesis	O
for	O
Alzheimer	O
's	I:C0002395
Disease	I:C0002395
.	O

N	O
-	I:C1706793
Terminal	I:C1706793
Hypothesis	O
for	O
Alzheimer	B:C0002395
's	I:C0002395
Disease	I:C0002395
.	O

Although	O
the	O
amyloid	B:C0002716
(	O
abeta	O
peptide	I:C0078939
,	O
Aβ	O
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
pathogenesis	O
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	O
,	O
it	O
is	O
still	O
controversial	O
.	O

Although	O
the	O
amyloid	O
(	O
abeta	B:C0078939
peptide	I:C0078939
,	O
Aβ	O
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
pathogenesis	O
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	O
,	O
it	O
is	O
still	O
controversial	O
.	O

Although	O
the	O
amyloid	O
(	O
abeta	O
peptide	I:C0078939
,	O
Aβ	B:C0078939
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
pathogenesis	O
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	O
,	O
it	O
is	O
still	O
controversial	O
.	O

Although	O
the	O
amyloid	O
(	O
abeta	O
peptide	I:C0078939
,	O
Aβ	O
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	B:C3161035
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
pathogenesis	O
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	O
,	O
it	O
is	O
still	O
controversial	O
.	O

Although	O
the	O
amyloid	O
(	O
abeta	O
peptide	I:C0078939
,	O
Aβ	O
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
pathogenesis	O
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	O
,	O
it	O
is	O
still	O
controversial	O
.	O

Although	O
the	O
amyloid	O
(	O
abeta	O
peptide	I:C0078939
,	O
Aβ	O
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
)	O
pathogenesis	O
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	O
,	O
it	O
is	O
still	O
controversial	O
.	O

Although	O
the	O
amyloid	O
(	O
abeta	O
peptide	I:C0078939
,	O
Aβ	O
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
pathogenesis	B:C0699748
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	O
,	O
it	O
is	O
still	O
controversial	O
.	O

Although	O
the	O
amyloid	O
(	O
abeta	O
peptide	I:C0078939
,	O
Aβ	O
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
pathogenesis	O
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	B:C0087111
,	O
it	O
is	O
still	O
controversial	O
.	O

One	O
possible	O
reason	O
is	O
a	O
lack	O
of	O
a	O
mechanistic	O
path	O
from	O
the	O
cleavage	O
products	O
of	O
the	O
amyloid	B:C0085151
precursor	I:C0085151
protein	I:C0085151
(	O
amyloid	O
precursor	I:C0085151
protein	I:C0085151
)	O
such	O
as	O
soluble	O
Aβ	O
monomer	O
and	O
soluble	O
molecular	O
fragments	O
to	O
the	O
deleterious	O
effects	O
on	O
synaptic	O
form	I:C0597545
and	O
function	O
.	O

One	O
possible	O
reason	O
is	O
a	O
lack	O
of	O
a	O
mechanistic	O
path	O
from	O
the	O
cleavage	O
products	O
of	O
the	O
amyloid	O
precursor	I:C0085151
protein	I:C0085151
(	O
amyloid	B:C0085151
precursor	I:C0085151
protein	I:C0085151
)	O
such	O
as	O
soluble	O
Aβ	O
monomer	O
and	O
soluble	O
molecular	O
fragments	O
to	O
the	O
deleterious	O
effects	O
on	O
synaptic	O
form	I:C0597545
and	O
function	O
.	O

One	O
possible	O
reason	O
is	O
a	O
lack	O
of	O
a	O
mechanistic	O
path	O
from	O
the	O
cleavage	O
products	O
of	O
the	O
amyloid	O
precursor	I:C0085151
protein	I:C0085151
(	O
amyloid	O
precursor	I:C0085151
protein	I:C0085151
)	O
such	O
as	O
soluble	O
Aβ	O
monomer	O
and	O
soluble	O
molecular	O
fragments	O
to	O
the	O
deleterious	O
effects	O
on	O
synaptic	B:C0597545
form	I:C0597545
and	O
function	O
.	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	B:C0023866
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	B:C0034036
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	B:C0678594
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	B:C0078939
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	B:C0679083
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	B:C0206249
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	B:C2259198
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	B:C1167622
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	B:C0003250
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	B:C4043101
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	I:C0034036
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	I:C0206249
term	I:C0206249
potentiation	I:C0206249
measurements	O
with	O
inhibition	O
binding	I:C2259198
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	I:C0003250
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	B:C1706793
-	I:C1706793
terminal	I:C1706793
domains	I:C1706793
of	O
neurotoxic	O

Aβ	B:C0078939
oligomers	I:C0078939
are	O
implicated	O
in	O
causing	O
the	O
disease	O
.	O

Aβ	O
oligomers	I:C0078939
are	O
implicated	O
in	O
causing	O
the	O
disease	B:C0012634
.	O

